Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

NCT01706120 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

National Cancer Institute, Naples

Collaborators

[object Object]